Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced-Dose Thrombolysis in Intermediate-High Risk Pulmonary Embolism, a Multicenter, Randomized Controlled Trial

NCT07917078 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07917078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced-Dose Thrombolysis in Intermediate-High Risk Pulmonary Embolism, a Multicenter, Randomized Controlled Trial
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
December 31, 2029
Enrollment
270 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Reduced-Dose Alteplase and Standard Anticoagulation Active comparatorAlteplase, Standard Anticoagulation

    Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) and reduced-dose alteplase \[25 mg continuous intravenous infusion for 2 hours\]

  • Standard Anticoagulation Active comparatorStandard Anticoagulation

    Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH)

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in the ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter (RVED/LVED) as measured by echocardiography Between baseline and 48 hours

Lead sponsor's other trials

China National Center for Cardiovascular Diseases, most recent start first.

Similar trials

Same condition (Pulmonary Embolism) and phase, most recent start first.